The challenge of sepsis
Year: 2025
Type: article
Abstract: To paraphrase Jane Austen, it is a truth universally acknowledged that sepsis has been one of the most difficult and frustrating clinical challenges of the last 50 years. Despite literally thousands of scientific papers and tens of thousands of patients enrolled in clinical trials, the clinical syndrome that we call sepsis continues to be responsible for approximately 20% of all deaths worldwide (Meyer, 2024). Unlike some of the major infective challenges that are largely restricted to certain geographical regions-such as malaria in sub-Saharan Africa and the Far East, or gastrointestinal infections in South Asia-sepsis is a global threat, as recognized by the World Health Organization (WHO) in its 2017 Resolution (WHO 2017). It is a sobering thought that even the most advanced economies deploying sophisticated intensive care methods have made only modest inroads into reducing sepsis-related mortality.Why has this been so difficult?As Hancock et al. point out in their lead article (Hancock et al. 2025), sepsis is a prototypic syndrome with a bewildering array of symptoms and signs, a multitude of causes, and an impact that stretches from a relatively mild self-limiting illness to an acute, life-threatening disease. Little wonder then that it has proved so challenging. The difficulties in establishing a single epidemiological definition have made it almost impossible to enroll a homogeneous population into clinical trials and has greatly hindered the investigation of new treatments.Meanwhile, at the bedside, it is usually relatively junior clinical staff who struggle to recognize the condition at an early enough stage to start treatment early. Hancock et al. make the case that the use of systems immunology tools have the potential to dissect this heterogeneous population into specific subgroups-"endotypes"-early in the clinical presentation to help predict the disease course and select treatments that will specifically address the pathological molecular dysfunction. This approach-an example of the concept of precision medicine-will depend for its success on (at least) three elements. First, it requires that the "omic profile" is consistent and reproducible in terms of the clinical phenotype and the clinical and geographic context of the patient. This is still a work in progress; Garduno and others (Garduno, 2023) have helpfully reviewed the range of different approaches to creating stable endotypes. Secondly, it will be important to understand how these endotypes evolve longitudinally in individual patients, a point rightly emphasized by Hancock et al. One of the clinical challenges is that patients with sepsis present at widely differing points in their clinical course; we need to understand how the omic profile changes over time and how this should be interpreted. Finally, at a practical level, all of this depends on the availability of simple, widely available diagnostic tests that can used quickly and easily in emergency departments, and clearly this is still a long way off.There is also an interesting conceptual question as to whether omics-based endotypes are sufficient alone to adequately identify patients and allow specific therapeutic interventions.Garduno (Garduno, 2023) summarized a number of small clinical trials in which immunologic manipulations were deployed based on an immunophenotypical abnormality: thus far the outcomes have not been particularly successful. One component of the equation that seems missing at present is the causative organism, a point also made by others (Giamerellos-Bourboulis, 2024). While sepsis is in many respects a final common pathway of injury following infection, different bacteria (and viruses) lead to quite different clinical and immunologic effects. For instance, Streptococcus pyogenes, a Gram-positive bacterium, can be associated with a toxic shock-like syndrome attributed to a superantigen effect, while the Gram-negative Vibrio vulnificus is associated with sepsis and necrotizing skin lesions. The challenge will be to incorporate complex omics data together with clinical and microbiologic information into what one might call an individual "therapeutic prescription".Post-sepsis, long COVID, and chronic fatigue syndrome-one and the same?One of the most intriguing insights to emerge in the post-COVID era is the apparent similarity between three seemingly distinct conditions. Chronic fatigue syndrome (CFS; known also as myalgic encephalitis or post-viral syndrome) has long been recognized as a variable constellation of symptoms and signs that often, but not always, follows an acute viral infection such as Epstein Barr virus. Characterized by profound fatigue lasting many months, and sometimes years, and a myriad of inconsistent immunologic findings, it has long frustrated both clinicians and patients because of the lack of a single diagnostic test and the absence of any effective treatment. Post-sepsis syndrome (PSS), recognized more recently, refers to the physical and in particular the neurocognitive, and neuropsychological consequences following acute sepsis. Finally, long COVID (or post-COVID syndrome), one of the most consequential long-term effects of the pandemic, also shows a wide range of manifestations, including significant neuropsychiatric, cardiovascular, and autoimmune phenomena, associated with evidence of immune dysregulation, mitochondrial abnormalities, and effects on the microbiome (Fleischman-Struzek, 2024). Hancock and colleagues focus on the similarities between PSS and long COVID, and describe gene expression studies which distinguish patients with an uncomplicated course from those who go on to develop long COVID. They speculate that epigenetic mechanisms may influence the development of both syndromes. Once again it seems to be possible to identify endotypes-that is, transcriptional patterns that co-locate with clinical phenotypes to identify different responses to acute infection.The challenge here is to disentangle the various clinical pathways that may be involved. Thus, patients with severe COVID often have a sepsis-like syndrome and often finish up on intensive care units (ICUs). If they develop persistent long-term symptoms, are they suffering from long COVID, or PSS, or simply post-ICU syndrome? But maybe, as Hancock et al. suggest, that is exactly the point: it does not really matter what label one attaches if indeed there is a shared pathological process. Elucidating the mechanism of these disease processes could perhaps allow therapeutic strategies applicable to all three disorders.As Hancock et al. point out, the extraordinary capability of systems biology supported by machine learning and artificial intelligence models offer the possibility of "getting under the skin" of the heterogeneity of sepsis and being able to identify subgroups of patients whose disease will evolve in a particular way, and perhaps also to specify "therapeutic prescriptions" for individual patients. It remains to be seen if this promise can be translated into actionable clinical decision-making tools. If it can, it is unrealistic to expect that it will be available to people in low-and middle-income countries, where the incidence of sepsisrelated death is perhaps 50-fold higher than in high-income countries (Rudd, 2020). Hancock et al. argue that sepsis (or at least, a clinical syndrome akin to sepsis) underlies most of the morbidity and mortality that accompanies serious pandemic infections, and more precise diagnosis will support more effective treatment. The WHO rightly points out that prevention is the best approach to mitigating serious infection: good personal hygiene, avoiding unclean water or poor sanitation, ensuring high vaccine uptake, and breastfeeding for newborns (WHO, 2024). Both strategies are worthy of further attention.
Source: Frontiers in Science
Author: Jonathan Cohen
Institution: Brighton and Sussex Medical School
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4408552595